The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer

Cantharidin, one of the active components of mylabris, is believed to have antitumor activity. Cantharidin selectively inhibits protein phosphatase 2A (PP2A), which can repress multiple oncogenic kinases (ERK, JNK, PKC, and NF-κB). Researches in vitro have shown that cantharidin suppresses cell viab...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncogenesis
Main Authors: Xu, Meng-Dan, Liu, Lu, Wu, Meng-Yao, Jiang, Min, Shou, Liu-Mei, Wang, Wen-Jie, Wu, Jing, Zhang, Yan, Gong, Fei-Ran, Chen, Kai, Tao, Min, Zhi, Qiaoming, Li, Wei
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6255842/
https://ncbi.nlm.nih.gov/pubmed/30478299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41389-018-0102-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados